Zydus receives tentative approval from the USFDA for Deferasirox Tablets

Deepthi | Myequity news | Date : 20-11-2018 12:20:00 IST

Zydus Cadila has received the tentative approval from the USFDA to market Deferasirox Tablets, 90 mg, 180 mg, and 360 mg (USRLD  Exjade  Tablets).It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

It is used to treat ongoing high levels of iron in the body caused by multiple blood transfusions. It is also used to treat high levels of iron in people with a certain blood disorder who do not require blood transfusions (non—transfusion—dependent thalassemia).

About Zydus Cadila:

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research—based pharmaceutical company by 2020


More from Myequity